S&P Plunges on Inflation Fears
The S&P 500 moved lower on Friday as recent consumer sentiment data fueled concerns around inflation.The Dow Jones Industrials lost 71.86 points to 44,675.77. The much-broader index dumped 12.15 points to 6,071.42The tech-heavy NASDAQ gave back 100.74 points to 19,691.26. Amazon lost 2%, weighing on sentiment. Guidance from the e-commerce giant disappointed investors, as Amazon called for revenue growth of 5% to 9% in the first quarter — its weakest growth on record. The outlook overshadowed top- and bottom-line beats in the fourth quarter.Meanwhile, January’s jobs report released Friday showed 143,000 jobs were added for the month, but traders were concentrating on other parts of the report. The unemployment rate actually fell to 4% from 4.1%, and December’s and November’s jobs figures were revised up significantly. Average hourly earnings for January were also higher than expected, raising inflation fears.Consumer sentiment fell in February to 67.8, according to a preliminary reading of the University of Michigan’s consumer sentiment index. Economists polled by Dow Jones had expected 71.3.Prices for the 10-year Treasury eased a bit, raising yields to 4.51% from Thursday’s 4.44%. Treasury prices and yields move in opposite directions.Oil prices gained 65 cents to $71.26 U.S. a barrel. Prices for gold revived $29.30 an ounce to $2,906 U.S.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


